Rudolph Navari to Prognosis
This is a "connection" page, showing publications Rudolph Navari has written about Prognosis.
Connection Strength
0.051
-
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540.
Score: 0.023
-
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995 Sep; 13(9):2408-16.
Score: 0.019
-
Bone marrow necrosis in acute leukemia. Acta Haematol. 1983; 69(3):158-63.
Score: 0.008